Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome

This study is currently recruiting participants.
Verified September 2011 by Washington University School of Medicine
Sponsor:
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT00565903
First received: November 29, 2007
Last updated: September 22, 2011
Last verified: September 2011
  Purpose

Pleuropulmonary Blastoma (PPB) is a rare lung tumor which develops in childhood. The underlying genetic factors which contribute to the development and progression of PPB is not defined. We are working to identify the genetic factors which may contribute to the development of this rare tumor.


Condition
Pleuropulmonary Blastoma
Cystic Nephroma

Study Type: Observational
Study Design: Observational Model: Family-Based
Time Perspective: Prospective
Official Title: Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome

Resource links provided by NLM:


Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:
  • Identify the genetic factors which contribute to the development or progression of pleuropulmonary blastoma [ Time Frame: 10 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Define the clinical features of the pleuropulmonary blastoma (PPB) familial cancer syndrome. [ Time Frame: 10 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

We are collecting blood samples or saliva samples. When available, we also collect tumor samples from prior surgical procedures.


Estimated Enrollment: 2000
Study Start Date: March 2005
Estimated Study Completion Date: March 2015
  Eligibility

Ages Eligible for Study:   up to 95 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Families who have a child or adult with pleuropulmonary blastoma or cystic nephroma are invited to participate.

Criteria

Inclusion Criteria:

  • child or adult diagnosed with pleuropulmonary blastoma or cystic nephroma.

Exclusion Criteria:

  • child or adult who does not have a confirmed diagnosis of pleuropulmonary blastoma or cystic nephroma.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00565903

Contacts
Contact: Paul Goodfellow, Ph.D. 314-362-2032 goodfellowp@wudosis.wustl.edu
Contact: Jennifer L. Ivanovich, MS, MBA 314-454-5076 jen@ccadmin.wustl.edu

Locations
United States, Missouri
Washington University School of Medicine Recruiting
St. Louis, Missouri, United States, 63110
Contact: Paul Goodfellow, PhD     314-362-2032     goodfellowp@wudosis.wustl.edu    
Contact: Jennifer Ivanovich, MS, MBA     314-454-5076     jen@ccadmin.wustl.edu    
Principal Investigator: Paul Goodfellow, PhD            
Sub-Investigator: Jennifer Ivanovich, MS, MBA            
Sub-Investigator: Ashley Hill, MD            
Sponsors and Collaborators
Washington University School of Medicine
Investigators
Principal Investigator: Paul Goodfellow, PhD Washington University School of Medicine
Study Director: Jennifer Ivanovich, MS, MBA Washington University School of Medicine
Study Chair: Ashley Hill, MD Children's Research Institute
Study Chair: Jack Priest, MD Children's Hospital and Clinics of Minnesota
  More Information

Additional Information:
No publications provided

Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT00565903     History of Changes
Other Study ID Numbers: 05-0192 / 201012830
Study First Received: November 29, 2007
Last Updated: September 22, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Washington University School of Medicine:
pleuropulmonary blastoma
PPB
cystic nephroma

Additional relevant MeSH terms:
Pulmonary Blastoma
Neoplasms, Complex and Mixed
Neoplasms by Histologic Type
Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on June 13, 2013